Kivu Bioscience

Kivu Bioscience is a US-based biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) that aim to improve cancer treatment outcomes through targeted therapies. Kivu Bioscience was founded in 2024 in San Francisco, US, concentrating on biopharmaceutical developments. The company has engaged in a strategic pivot towards enhancing its oncology programs, resulting in a successful Series A funding round. It raised USD 92.

00 mn on October 28, 2024, led by Novo Holdings, with participation from BOM Brabant Ventures, BioGeneration Ventures, Gimv, HealthCap, M Ventures, and Red Tree Venture Capital. The founder’s background and previous ventures are currently undisclosed. Kivu Bioscience specializes in the development of next-generation antibody-drug conjugates (ADCs) that target various forms of cancer. Its core offerings leverage proprietary technologies, such as the Synaffix site-specific conjugation platform and GlycoConnect™ technology, to create highly stable and effective ADCs.

These products are designed to optimize therapeutic efficacy while minimizing off-tumor toxicity by utilizing advanced linker and payload combinations. Kivu's ADCs focus on enhancing homogeneity, stability, and potency, thus aiming to provide targeted cancer therapies with improved safety profiles. The company targets global markets, particularly in North America and Europe, addressing significant unmet medical needs of patients suffering from various malignancies. Kivu Bioscience has successfully raised significant capital through its Series A financing round of USD 92.

00 mn. Its revenue model revolves around partnerships and collaborations with other biopharmaceutical entities, focusing on the co-development and commercialization of ADCs. Transactions are structured through agreements that may include milestone payments and royalties, providing a framework for shared investment in research and development efforts. While specific pricing details for its ADC products are not disclosed, the company targets biopharma partners looking for innovative therapeutics that can be integrated into their oncology pipelines, suggesting a B2B approach in its revenue generation strategy.

In October 2024, Kivu Bioscience raised USD 92. 00 mn in Series A funding led by Novo Holdings, which will be utilized to advance its multiple oncology programs into the clinic. The company is focused on launching new ADC products designed to meet the needs of various cancer treatments, with plans to expand into new markets in North America and Europe by 2025. The recent funding will support these initiatives, helping to progress their innovative therapies towards clinical applications.